#1 Clinical Trials Search in Europe

Piperacillin

Piperacillin is a broad-spectrum antibiotic commonly used to treat various bacterial infections. This article examines several clinical trials investigating the use of piperacillin, often in combination with tazobactam, in different patient populations and conditions. These studies aim to optimize dosing regimens, evaluate effectiveness, and explore potential alternatives to reduce antibiotic resistance.

Table of Contents

What is Piperacillin?

Piperacillin is a powerful antibiotic that belongs to the class of drugs called beta-lactam antibiotics. It is often used to treat serious bacterial infections, especially those caused by resistant organisms. Piperacillin is frequently combined with another drug called tazobactam, forming a combination known as piperacillin-tazobactam. This combination is sometimes referred to by the brand name Tazocin[1].

What Conditions Does Piperacillin Treat?

Piperacillin and piperacillin-tazobactam are used to treat a variety of serious bacterial infections, including:

  • Septic shock: A life-threatening condition caused by a severe infection that leads to dangerously low blood pressure[2]
  • Late-onset neonatal sepsis: A serious blood infection in newborn babies[3]
  • Ventilator-associated pneumonia: A lung infection that occurs in patients on mechanical ventilation[4]
  • Infections in critically ill patients: Various types of severe infections in patients in intensive care units[5]
  • Infections in patients undergoing hematopoietic stem cell transplantation: These patients are at high risk of infections due to weakened immune systems[6]

How Does Piperacillin Work?

Piperacillin works by interfering with the cell wall formation of bacteria. It belongs to a group of antibiotics called beta-lactams, which kill bacteria by preventing them from building their protective outer layer. This action makes the bacteria vulnerable and ultimately leads to their death[2].

Piperacillin in Combination Therapy

Piperacillin is often combined with tazobactam to form piperacillin-tazobactam. Tazobactam is not an antibiotic itself, but it helps piperacillin work better. It does this by blocking certain enzymes (called beta-lactamases) that some bacteria produce to resist antibiotics. This combination allows piperacillin-tazobactam to be effective against a wider range of bacteria, including some that are resistant to other antibiotics[7].

Dosing and Administration

Piperacillin-tazobactam is typically given intravenously (through a vein) in a hospital setting. The dosage and duration of treatment can vary depending on the type and severity of infection, as well as the patient’s age, weight, and kidney function. Some common dosing regimens include:

  • For adults with normal kidney function: 4.5 grams every 6 hours[8]
  • For preterm neonates: Dosing may be based on gestational age, ranging from 30 mg/kg to 50 mg/kg every 8 hours[3]
  • For children: Dosing is often based on weight, with adjustments made for kidney function[9]

In some cases, piperacillin-tazobactam may be given as an extended infusion over several hours, which can help maintain effective levels of the antibiotic in the body for a longer period[2].

Use in Special Populations

Piperacillin-tazobactam dosing may need to be adjusted in certain patient groups:

  • Patients with kidney problems: The dose may need to be reduced as piperacillin and tazobactam are primarily eliminated by the kidneys[1]
  • Critically ill patients: These patients may have altered drug metabolism and may require specialized dosing strategies[5]
  • Neonates and young children: Dosing is typically based on weight and age, with careful monitoring required[9]

Ongoing Research and Clinical Trials

Several clinical trials are currently investigating various aspects of piperacillin-tazobactam use, including:

  • Optimizing dosing strategies in critically ill patients[5]
  • Comparing piperacillin-tazobactam to other antibiotics for specific infections[4]
  • Studying its use as a preventive measure in high-risk patients[6]
  • Investigating its effectiveness against resistant bacteria[7]

These ongoing studies aim to improve our understanding of how to use piperacillin-tazobactam most effectively and safely in different patient populations.

Aspect Details
Patient Populations Preterm neonates, critically ill patients, patients with renal dysfunction, hematopoietic stem cell transplant recipients
Conditions Studied Late-onset neonatal sepsis, severe sepsis, septic shock, ventilator-associated pneumonia, bacterial infections
Dosing Strategies Model-based dosing, extended infusion, continuous infusion, renal function-adjusted dosing
Primary Outcomes Clinical efficacy, pharmacokinetic parameters, mortality rates, microbiological outcomes
Secondary Outcomes Length of hospital stay, adverse events, cost-effectiveness, antimicrobial resistance patterns
Key Challenges Optimizing dosing in diverse patient populations, managing antibiotic resistance, balancing efficacy and safety
Potential Benefits Improved treatment outcomes, reduced antibiotic resistance, alternatives to last-resort antibiotics, optimized patient care

FAQ

  • What is piperacillin and how is it used? Piperacillin is a broad-spectrum antibiotic often used in combination with tazobactam to treat various bacterial infections. It is commonly used in hospital settings, particularly for severe infections or in critically ill patients.
  • Why are clinical trials studying piperacillin important? Clinical trials on piperacillin are important to optimize dosing regimens, evaluate its effectiveness in different patient populations, and explore alternatives to reduce antibiotic resistance. These studies help improve treatment outcomes and patient care.
  • What types of patients are being studied in these piperacillin trials? The clinical trials involve various patient groups, including preterm neonates with sepsis, critically ill patients, individuals with renal dysfunction, and patients undergoing hematopoietic stem cell transplantation.
  • How does piperacillin dosing differ in various patient populations? Dosing of piperacillin can vary based on factors such as age, renal function, and severity of infection. For example, preterm neonates may require different dosing than adults, and patients with renal dysfunction may need dose adjustments.
  • What are some potential benefits of optimizing piperacillin use? Optimizing piperacillin use can lead to improved treatment outcomes, reduced risk of antibiotic resistance, and potentially decreased healthcare costs. It may also help in finding alternatives to last-resort antibiotics like carbapenems.

Ongoing Clinical Trials on Piperacillin

  • Early Stopping of Antibiotic Treatment in Children with Cancer and Febrile Neutropenia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • A study on the use of vancomycin and a drug combination for treating infections in children through continuous antibiotic infusion.

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study of Piperacillin and Tazobactam Given Under the Skin Compared to a Vein in Patients with Infectious Diseases

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Comparing piperacillin-tazobactam and meropenem for treating bloodstream infections caused by cephalosporin-resistant bacteria in adult patients

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark

  • Study on Antibiotic Levels in Blood of Pregnant Women with Twins Using Piperacillin, Tazobactam, Cefazolin, Ampicillin Sodium, and Clindamycin

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria

  • Study of Piperacillin/Tazobactam and Levofloxacin for Patients with COPD or Cystic Fibrosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Shortened Antibiotic Treatment for Gram-negative Bacteremia in Hospitalized Adults Using Pivmecillinam Hydrochloride and Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark

  • Study on Post-Surgery Antibiotic Use for Patients with Biliary Stents Undergoing Pancreaticoduodenectomy: Piperacillin and Tazobactam Evaluation

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Piperacillin: A broad-spectrum antibiotic used to treat various bacterial infections, often combined with tazobactam.
  • Tazobactam: A beta-lactamase inhibitor combined with piperacillin to enhance its effectiveness against certain bacteria.
  • Sepsis: A life-threatening condition caused by the body's extreme response to an infection, which can lead to tissue damage, organ failure, and death.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and therapeutic effects.
  • Extended-spectrum beta-lactamase (ESBL): Enzymes produced by some bacteria that can break down certain antibiotics, making them resistant to treatment.
  • Ventilator-associated pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Renal dysfunction: Impaired kidney function that can affect how drugs are processed and eliminated from the body.
  • Hematopoietic stem cell transplantation: A procedure that replaces damaged or diseased bone marrow with healthy stem cells, often used to treat blood cancers and disorders.
  • Carbapenem: A class of powerful antibiotics often considered as last-resort treatment for severe bacterial infections.

References

  1. https://clinicaltrials.gov/study/NCT00816790
  2. https://clinicaltrials.gov/study/NCT02820987
  3. https://clinicaltrials.gov/study/NCT05981079
  4. https://clinicaltrials.gov/study/NCT04276480
  5. https://clinicaltrials.gov/study/NCT03738683
  6. https://clinicaltrials.gov/study/NCT01714557
  7. https://clinicaltrials.gov/study/NCT00488189
  8. https://clinicaltrials.gov/study/NCT02730624
  9. https://clinicaltrials.gov/study/NCT02466438